Latest News
-
Thursday - November 23, 2017
Bayer eases dairy herd health management with "BCS Cowdition" application update
Bayer’s BCS Cowdition smartphone application simplifies and standardizes body condition scoring (BCS) to help farmers and vets identify, tackle and prevent metabolic and fertility problems in dairy cows / Innovative updates to BCS Cowdition enables tailored individual cow assessments, and offers a comprehensive herd dashboard, and further insights garnered from "big data" » more
-
Thursday - November 16, 2017
Not intended for U.S. and UK Media
Bayer and PeptiDream to identify new active substance candidates through novel peptide-based screening technology » more
-
Wednesday - November 15, 2017
Heiko Schipper to join Bayer Board of Management and head Consumer Health Division
Erica Mann to leave Bayer effective March 31, 2018 » more
-
Tuesday - November 14, 2017
Not intended for U.S. and UK Media
Bayer and Loxo Oncology to develop and commercialize two novel oncology therapies selectively targeting genetic drivers of cancer
Larotrectinib (LOXO-101) and LOXO-195 target tropomyosin receptor kinase (TRK) fusion proteins, which are a product of genetic alterations that occur across a range of different tumors / Co-Promotion of the products in the U.S. / Bayer solely responsible for the commercialization of both products outside the U.S. / U.S. filing of larotrectinib planned for late 2017 or early 2018 » more
-
Monday - April 24, 2017
World Malaria Day 2017:
Bayer partners with Goodbye Malaria to help “End Malaria for Good” » more
-
Tuesday - December 13, 2016
Monsanto Shareowners Approve Merger with Bayer
Key Milestone in Merger to Create a Global Leader in Agriculture / Close of Transaction Expected by the End of 2017 » more
-
Monday - December 12, 2016
Bayer and Versant Ventures Join Forces to Launch Stem Cell Therapy Company BlueRock Therapeutics with USD 225 Million Series A Financing
BlueRock Therapeutics is focused on breakthrough treatments based on latest stem cell technology in combination with superior cell differentiation protocols / BlueRock Therapeutics’ vision is to cure diseases with significant cell loss and diminished self-repair potential with an initial focus on cardiovascular, neurological and other conditions » more
Copyright @ Bayer AG
Search
Publications
Newsletter
Events
Thursday, February 27, 2020
Financial News Conference on the Full Year 2019 Results
Additional Press Events
Investor Relations Events
BayKomm Events
Download Center - Selection
Bayer TV